Shibamoto Y - Search Results

1

The Japanese experiences with hypoxia-targeting pharmacoradiotherapy: from hypoxic cell sensitisers to radiation-activated prodrugs.

Shibamoto Y, Sugie C, Ito M, Ogino H. Shibamoto Y, et al. Expert Opin Pharmacother. 2004 Dec;5(12):2459-67. doi: 10.1517/14656566.5.12.2459. Expert Opin Pharmacother. 2004. PMID: 15571464 Review.

2

In vivo radiosensitizing activity of a new fluorinated hypoxic cell radiosensitizer, KU-2285, in combination with radiation dose fractionation.

Sasai K, Fushiki M, Yukawa Y, Suyama S, Iwai H, Shibamoto Y, Nishimoto S, Takahashi M, Abe M. Sasai K, et al. Among authors: shibamoto y. Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1231-4. doi: 10.1016/0360-3016(91)90280-h. Int J Radiat Oncol Biol Phys. 1991. PMID: 1938521

3

[Developments in the experimental methods of evaluating hypoxic cell sensitizers].

Shibamoto Y, Sasai K, Takahashi M, Abe M. Shibamoto Y, et al. Gan No Rinsho. 1988 Oct;34(13):1859-63. Gan No Rinsho. 1988. PMID: 3199519 Japanese.

4

Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay.

Shibata T, Shibamoto Y, Sasai K, Oya N, Murata R, Takagi T, Hiraoka M, Takahashi M, Abe M. Shibata T, et al. Among authors: shibamoto y. Br J Cancer Suppl. 1996 Jul;27:S61-4. Br J Cancer Suppl. 1996. PMID: 8763848 Free PMC article.

5

A phase I/II study of a hypoxic cell radiosensitizer KU-2285 in combination with intraoperative radiotherapy.

Shibamoto Y, Ohshio G, Hosotani R, Nishimura Y, Manabe T, Imamura M, Abe M. Shibamoto Y, et al. Br J Cancer. 1997;76(11):1474-9. doi: 10.1038/bjc.1997.580. Br J Cancer. 1997. PMID: 9400944 Free PMC article. Clinical Trial.

6

Effect of a hypoxic cell sensitizer doranidazole on the radiation-induced apoptosis of mouse L5178Y lymphoma cells.

Aoki M, Furusawa Y, Shibamoto Y, Kobayashi A, Tsujitani M. Aoki M, et al. Among authors: shibamoto y. J Radiat Res. 2002 Jun;43(2):161-6. doi: 10.1269/jrr.43.161. J Radiat Res. 2002. PMID: 12238330 Free article.

7

Comparison of 5-fluorouracil and 5-fluoro-2'-deoxyuridine as an effector in radiation-activated prodrugs.

Shibamoto Y, Mimasu Y, Tachi Y, Hatta H, Nishimoto S. Shibamoto Y, et al. J Chemother. 2002 Aug;14(4):390-6. doi: 10.1179/joc.2002.14.4.390. J Chemother. 2002. PMID: 12420858

8

Accumulation of Tc-99m HMDP in bony structures of immature teratoma in a child.

Tohyama J, Ohba S, Sugie C, Ogino H, Hara M, Shibamoto Y. Tohyama J, et al. Among authors: shibamoto y. Clin Nucl Med. 2003 Apr;28(4):334-5. doi: 10.1097/01.RLU.0000057617.38638.3E. Clin Nucl Med. 2003. PMID: 12642721 No abstract available.

9

Radiographic findings of aberrant right subclavian artery initially depicted on CT.

Hara M, Satake M, Itoh M, Ogino H, Shiraki N, Taniguchi H, Shibamoto Y. Hara M, et al. Among authors: shibamoto y. Radiat Med. 2003 Jul-Aug;21(4):161-5. Radiat Med. 2003. PMID: 14514122

10

In vitro and in vivo evaluation of novel antitumor prodrugs of 5-fluoro-2'-deoxyuridine activated by hypoxic irradiation.

Shibamoto Y, Tachi Y, Tanabe K, Hatta H, Nishimoto S. Shibamoto Y, et al. Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):397-402. doi: 10.1016/j.ijrobp.2003.09.048. Int J Radiat Oncol Biol Phys. 2004. PMID: 14751508

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

595 results

Search Page

Filters